The multi-year partnership launches with focus on epilepsy, rare disease and AISAN FRANCISCO and ATLANTA, Dec. 02, 2025 (GLOBE NEWSWIRE)…
Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology…
NAPLES, FL / ACCESS Newswire / December 2, 2025 / Stemtech Corporation, the global leader and pioneer in stem cell…
Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trialsCAMBRIDGE, Mass., Dec.…
VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company…
~ New U.S. Patent Extends Protection Through 2042 ~~ Patent Allowance Secures Highest Level of Intellectual Property Protection for MPAR®…
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease…
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase…
PolarityBio thanks the clinical trial sites and, most importantly, the participants, for making this milestone in DFU biologic therapy development…
Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval PathwayPRINCETON, N.J., Dec. 02, 2025 (GLOBE…